ReviewNature reviews. Endocrinology2011
Novel etiopathophysiological aspects of thyrotoxic periodic paralysis.
Review in Nature reviews. Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 83 citations in OpenAlex.
- Thyrotoxicosis presenting with periodic paralysis in a young male: a case report.Annals of medicine and surgery (2012) · 2026Article
- Article
- Article
- Thyrotoxic Hypokalemic Periodic Paralysis Induced by High-Dose Insulin in an Adolescent Male with Type 1 Diabetes Mellitus.Hormone research in paediatrics · 2026Article
- Hyperthyroid Hypokalemic Periodic Paralysis in a Nepali Male; A Case Report.Clinical case reports · 2025Article
- Hyperthyroidism in Disguise: A Case of New-Onset Atrial Fibrillation and Acute Reversible Paralysis.JCEM case reports · 2025Article
- Molecular genetics of skeletal muscle channelopathies.Journal of human genetics · 2025Review
- Review
- Periodic paralysis.Handbook of clinical neurology · 2024Review
- A single-center retrospective study on the clinical features of thyrotoxic periodic paralysis.PloS one · 2024Article
- Article
- Thyrotoxic hypokalemic periodic paralysis and COVID-19 infection.Journal of family medicine and primary care · 2022Article
- Novel compound heterozygous mutation ofWorld journal of clinical cases · 2022Article
- [Clinical-epidemiological profile of patients with thyrotoxic periodic paralysis in two peruvian hospitals].Revista medica del Instituto Mexicano del Seguro Social · 2022Observational
- Hypokalemic paralysis in hyperthyroidism: Not all that glitter are gold.Clinical case reports · 2021Article
- A 29-year-old Bodybuilder with Liothyronine-induced Thyrotoxic Hypokalaemic Periodic Paralysis.European journal of case reports in internal medicine · 2021Article
- Article
- Impact of first-line treatment choice on long-term outcomes of hyperthyroid Graves' disease patients with thyrotoxic periodic paralysis.Journal of clinical & translational endocrinology · 2020Article
- Thyrotoxic periodic paralysis presenting in an African-American teenage male: case report.International journal of pediatric endocrinology · 2020Article
- Thyrotoxic periodic paralysis: A retrospective, observational study from India.The Indian journal of medical research · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyrotoxicosis can lead to thyrotoxic periodic paralysis (TPP), an endocrine channelopathy, and is the most common cause of acquired periodic paralysis. Typically, paralytic attacks cease when hyperthyroidism is abolished, and recur if hyperthyroidism returns. TPP is often underdiagnosed, as it has diverse periodicity, duration and intensity. The age at which patients develop TPP closely follows the age at which thyrotoxicosis occurs. All ethnicities can be affected, but TPP is most prevalent in people of Asian and, secondly, Latin American descent. TPP is characterized by hypokalemia, suppressed TSH levels and increased levels of thyroid hormones. Nonselective β adrenergic blockers, such as propranolol, are an efficient adjuvant to antithyroid drugs to prevent paralysis; however, an early and definitive treatment should always be pursued. Evidence indicates that TPP results from the combination of genetic susceptibility, thyrotoxicosis and environmental factors (such as a high-carbohydrate diet). We believe that excess T(3) modifies the insulin sensitivity of skeletal muscle and pancreatic β cells and thus alters potassium homeostasis, but only leads to a depolarization-induced acute loss of muscle excitability in patients with inherited ion channel mutations. An integrated etiopathophysiological model is proposed based on molecular findings and knowledge gained from long-term follow-up of patients with TPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.